Home LiteratureArticle Details
PMID: 21810604 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 187 ·No. 5 ·2011-09-01 ·Pages 2181-92

Sharda DR, Yu S, Ray M, Squadrito ML, De Palma M, Wynn TA, Morris SM, Hankey PA

Abstract

M1 activation of macrophages promotes inflammation and immunity to intracellular pathogens, whereas M2 macrophage activation promotes resolution of inflammation, wound healing, and tumor growth. These divergent phenotypes are characterized, in part, by the expression of inducible NO synthase and arginase I (Arg1) in M1 versus M2 activated macrophages, respectively. In this study, we demonstrate that the Ron receptor tyrosine kinase tips the balance of macrophage activation by attenuating the M1 phenotype while promoting expression of Arg1 through a Stat6-independent mechanism. Induction of the Arg1 promoter by Ron is mediated by an AP-1 site located 433 bp upstream of the transcription start site. Treatment of primary macrophages with macrophage stimulating protein, the ligand for Ron, induces potent MAPK activation, upregulates Fos, and enhances binding of Fos to the AP-1 site in the Arg1 promoter. In vivo, Arg1 expression in tumor-associated macrophages (TAMs) from Ron(-/-) mice was significantly reduced compared with that in TAMs from control animals. Furthermore, we show that Ron is expressed specifically by Tie2-expressing macrophages, a TAM subset that exhibits a markedly skewed M2 and protumoral phenotype. Decreased Arg1 in TAMs from Ron(-/-) mice was associated with reduced syngeneic tumor growth in these animals. These findings indicate that Ron induces Arg1 expression in macrophages through a previously uncharacterized AP-1 site in the Arg1 promoter and that Ron could be therapeutically targeted in the tumor microenvironment to inhibit tumor growth by targeting expression of Arg1.

MeSH Terms
Animals Arginase/biosynthesis,genetics,immunology Cell Separation Flow Cytometry Gene Expression Gene Expression Regulation/immunology Macrophage Activation/immunology Macrophages/enzymology,immunology Mice Mice, Inbred C57BL Mice, Knockout Neoplasms, Experimental/immunology,metabolism Oligonucleotide Array Sequence Analysis Promoter Regions, Genetic Receptor Protein-Tyrosine Kinases/genetics,immunology,metabolism Signal Transduction/genetics,immunology Transcription Factor AP-1/genetics,immunology,metabolism
Chemicals
Transcription Factor AP-1 RON protein Receptor Protein-Tyrosine Kinases Arg1 protein, mouse Arginase
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Sharda Daniel R
Graduate Program in Pathobiology, Department of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, PA 16802, USA.
Yu Shan
Ray Manujendra
Squadrito Mario Leonardo
De Palma Michele
Wynn Thomas A
Morris Sidney M
Hankey Pamela A
References (45)
45 references, click to expand
  1. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.
    Proc Natl Acad Sci U S A. 2007 May 1;104(18):7570-5 PMID: 17456594
  2. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival.
    Int J Oncol. 2000 Sep;17(3):445-51 PMID: 10938382
  3. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
    J Pathol. 2002 Mar;196(3):254-65 PMID: 11857487
  4. Enhancer-mediated control of macrophage-specific arginase I expression.
    J Immunol. 2004 Jun 15;172(12):7565-73 PMID: 15187136
  5. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.
    J Pathol. 2007 Dec;213(4):402-11 PMID: 17955509
  6. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
    Cancer Cell. 2005 Sep;8(3):211-26 PMID: 16169466
  7. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.
    J Immunol. 2001 Dec 1;167(11):6533-44 PMID: 11714822
  8. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase.
    J Immunol. 1999 Dec 15;163(12):6606-13 PMID: 10586055
  9. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
    Curr Drug Targets. 2010 Sep;11(9):1157-68 PMID: 20545605
  10. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells.
    Am J Physiol. 1998 Nov;275(5):E740-7 PMID: 9814991
  11. GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells.
    Oncogene. 2006 Apr 20;25(17):2433-43 PMID: 16314834
  12. Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production.
    Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):571-7 PMID: 17194896
  13. Arginine metabolism: nitric oxide and beyond.
    Biochem J. 1998 Nov 15;336 ( Pt 1):1-17 PMID: 9806879
  14. Inhibition of TLR4-induced IκB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein.
    J Immunol. 2010 Dec 15;185(12):7309-16 PMID: 21078906
  15. The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity.
    J Immunol. 2008 Aug 15;181(4):2303-10 PMID: 18684919
  16. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase.
    Genes Funct. 1997 Feb;1(1):69-83 PMID: 9680329
  17. Overexpression of the RON gene in human breast carcinoma.
    Oncogene. 1998 Jun 4;16(22):2927-33 PMID: 9671413
  18. Alternative activation of macrophages.
    Nat Rev Immunol. 2003 Jan;3(1):23-35 PMID: 12511873
  19. Development of monocytes, macrophages, and dendritic cells.
    Science. 2010 Feb 5;327(5966):656-61 PMID: 20133564
  20. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
    Oncogene. 2003 Jan 16;22(2):186-97 PMID: 12527888
  21. Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain.
    J Biol Chem. 2003 Aug 8;278(32):30083-90 PMID: 12766170
  22. Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine Ron receptor tyrosine kinase.
    J Biol Chem. 2005 Oct 21;280(42):35098-107 PMID: 16103119
  23. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
    J Immunol. 2005 Jan 15;174(2):636-45 PMID: 15634881
  24. The Ron receptor tyrosine kinase regulates acute lung injury and suppresses nuclear factor kappaB activation.
    Shock. 2007 Mar;27(3):274-80 PMID: 17304108
  25. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages.
    J Immunol. 2002 Jan 15;168(2):853-60 PMID: 11777982
  26. Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
    Cancer Cell. 2005 Mar;7(3):211-7 PMID: 15766659
  27. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
    Cancer Res. 2009 Mar 15;69(6):2506-13 PMID: 19244102
  28. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
    Cancer Res. 2005 Apr 15;65(8):3044-8 PMID: 15833831
  29. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta.
    Gene. 2005 Jun 20;353(1):98-106 PMID: 15922518
  30. SHIP represses the generation of alternatively activated macrophages.
    Immunity. 2005 Oct;23(4):361-74 PMID: 16226502
  31. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
    Cancer Res. 2009 Mar 15;69(6):2514-22 PMID: 19276342
  32. The phenotype of murine wound macrophages.
    J Leukoc Biol. 2010 Jan;87(1):59-67 PMID: 20052800
  33. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis.
    PLoS Pathog. 2009 Apr;5(4):e1000371 PMID: 19360123
  34. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity.
    J Biol Chem. 2005 Dec 2;280(48):40241-51 PMID: 16166096
  35. Tumour-educated macrophages promote tumour progression and metastasis.
    Nat Rev Cancer. 2004 Jan;4(1):71-8 PMID: 14708027
  36. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide.
    J Immunol. 2004 Feb 1;172(3):1825-32 PMID: 14734766
  37. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens.
    Nat Immunol. 2008 Dec;9(12):1399-406 PMID: 18978793
  38. Blood monocytes: development, heterogeneity, and relationship with dendritic cells.
    Annu Rev Immunol. 2009;27:669-92 PMID: 19132917
  39. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Cancer Res. 2004 Aug 15;64(16):5839-49 PMID: 15313928
  40. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior.
    Science. 2007 Aug 3;317(5838):666-70 PMID: 17673663
  41. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships.
    Blood. 2009 Jul 23;114(4):901-14 PMID: 19383967
  42. Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance.
    Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):365-71 PMID: 16284191
  43. Thrombin induces endothelial arginase through AP-1 activation.
    Am J Physiol Cell Physiol. 2010 Apr;298(4):C952-60 PMID: 20032511
  44. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases.
    J Biol Chem. 2000 Oct 6;275(40):31536-45 PMID: 10913131
  45. RON-regulated innate immunity is protective in an animal model of multiple sclerosis.
    Ann Neurol. 2005 Jun;57(6):883-95 PMID: 15929040
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
1550-6606
Published
2011-09-01
Epub
2011-00-01
Pages
2181-92
Language
English
Region
United States
NLM ID
2985117R
PMCID
PMC4042865
Subset
IM
Grants
Intramural NIH HHS · Z01 AI000829-10 · United States
NIGMS NIH HHS · R01 GM057384 · United States
NIAID NIH HHS · R29 AI043367 · United States
NIGMS NIH HHS · R01 GM57384 · United States
NIAID NIH HHS · R29 AI043367-05 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com